-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Lineage Cell Therapeutics, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and change rate from 2010 to Q1 2025.
- Lineage Cell Therapeutics, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending 31 Mar 2025 was $5.04M, a 64% decline year-over-year.
- Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $35.9M, a 458% increase from 2023.
- Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $6.42M, a 294% increase from 2022.
- Lineage Cell Therapeutics, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $1.63M, a 95.6% decline from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Change (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Change (%)